The Latest Breaking News from FDA

New COVID-19 boosters targeting today’s most common omicron strains should begin arriving within days

The GOP has understandably cast Anthony Fauci as a villain, but there are few plans to overhaul public health bureaucracies.

Persistent economic turbulence and an uncertain outlook have led investors to prioritize steady income generation from their investments. Hence, fundamentally sound dividend yielders with a solid track record and potential for perpetual growth Merck (MRK), Abbott (ABT), Cigna (CI), Energy Transfer (ET), and Kronos (KRO) could be permanent additions to…

The uncertainty surrounding the market and the economy because the Federal Reserve signaled to continue hiking interest rates is making investors seek low-risk investments. Given lower volatility and attractive dividend payments, Johnson & Johnson (JNJ), CVS Health (CVS), and Summit Financial Group (SMMF) could be good candidates to consider on…

Optimi Health (OTCQX: OPTHF) has released an operational update on its planned year of commercialization, including the launch of psychedelics catalog.

Government advisers are debating who should should get new updated COVID-19 boosters and when

On Sept. 1, 2022, the Centers for Disease Control and Prevention endorsed the use of updated COVID-19 booster shots that are specifically tailored to combat the two most prevalent omicron subvariants, BA.4 and BA.5. The decision comes just a day after the Food and Drug Administration’s emergency use authorization of…

Wall Street Journal

A federal judge in Riverside, California, declared a stem cell treatment firm operating in the state to be exempt from Food and Drug Administration regulations, opening the door to the further proliferation of clinics offering therapies the FDA says are scientifically unproven and potentially dangerous.